News

The phase II study recruited patients with mild to moderate psoriasis, a chronic skin disorder which creates an excess of skin cells that pile up on the skin

XL184 is the seventh drug to reach clinical development from the company’s internal discovery program within two years. Pending FDA clearance, Exelixis intends to initiate a phase I

Original data analyzed by two cardiologists threw up safety concerns around the drug suggesting it may damage the kidneys and even increase the risk of death. The following

The trial results showed that immediate-release Zegerid (omeprazole) powder for oral suspension 40mg to be more effective than Protonix (pantoprazole) delayed-release tablets 40mg when dosed once a day

The data reported at the American Diabetes Association (ADA) Annual Meeting in San Diego suggests that ruboxistaurin mesylate was effective in persons with type 2 diabetes and kidney

The revelation from the highly respected cancer investigation body has been made at the 9th International Conference on Malignant Lymphoma and comes in the wake of a study

Results from the VYVA (VYtorin Versus Atorvastatin) trial involving a subgroup of 428 patients with type 2 diabetes were evaluated. In the new analysis, results showed that Vytorin

The positive results were presented by principal investigator, Dr Barbara Pro, at the International Conference on Malignant Lymphoma in Lugano, Switzerland, following trials carried out at the M.D.

Silodosin is a novel alpha(1)-adrenoceptor antagonist with high uroselectivity. The company licensed silodosin from Kissei Pharmaceuticals Co., of Japan in April 2004, to develop and market silodosin in